Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia

To evaluate the efficacy, safety, and impact on hospitalizations of long-acting injectable paliperidone palmitate (PP) treatment, in patients with recent-onset schizophrenia who had not responded satisfactorily to oral antipsychotics. In this 18-month, open-label, Phase-IIIb study from Asia-Pacific...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychiatric disease and treatment 2015-01, Vol.11 (default), p.657-668
Main Authors: Zhang, Fan, Si, Tianmei, Chiou, Chiun-Fang, Harris, Anthony Wf, Kim, Chang Yoon, Jahagirdar, Padmashree, Ascher, Steve
Format: Article
Language:English
Subjects:
Antipsychotics
atypical antipsychotics
Care and treatment
Drug abuse
Hospital care
Hospitalization
long-acting injectables
Management
Mental disorders
Mental health
open-label
Original Research
paliperidone palmitate
Psychiatry
Psychotropic drugs
R&D
Research & development
Risk factors
Schizophrenia
Social research
Systematic review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the efficacy, safety, and impact on hospitalizations of long-acting injectable paliperidone palmitate (PP) treatment, in patients with recent-onset schizophrenia who had not responded satisfactorily to oral antipsychotics. In this 18-month, open-label, Phase-IIIb study from Asia-Pacific region, patients (18-50 years) with recent-onset (≤5 years) schizophrenia unsatisfactorily treated with previous oral antipsychotics were initiated on PP 150 mg eq on day 1, 100 mg eq on day 8, followed by flexible once monthly maintenance doses of 50-150 mg eq. The number and duration of hospitalizations were compared using a mirror analysis method between two periods: retrospective (12 months before PP initiation) and prospective (12 and 18 months after PP treatment) periods. A total of 303 out of 521 (58%) patients (mean age, 28.7 years; 65.5% men, 92.5% Asian) completed the study. Positive and Negative Syndrome Scale (PANSS) total score improved significantly from baseline to month 18 (mean [standard deviation, SD] change: -11.3 [21.38], P
ISSN:1176-6328
1178-2021
1178-2021
DOI:10.2147/NDT.S77778